Skip to main content
Caplight Logo









Trojan Bio

Trojan Bio

Private
Ness ZionaHealthcare & Life Scienceshttps://trojan-bio.com

Last Round

Seed

Jan 4, 2024

Est. Valuation

$3M

Total Funding Raised

$315,000

Company Overview

Trojan Bio operates in Healthcare & Life Sciences and is based in Ness Ziona. Its latest recorded funding round was a Seed round in January 2024.

Trojan Bio is a biotechnology company developing a novel class of therapeutic antibodies for the treatment of various cancers by harnessing antiviral immunity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Trojan Bio Comparables

Compare Trojan Bio with similar companies based on industry and business-model similarity.

Trojan Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VerImmune
85%
ViVac Pharma
82%
Biond Biologics
77%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Trojan Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 4, 2024
SeedOct 19, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Trojan Bio Investors

Notable investors and investment history

Trojan Bio investors
InvestorRounds
NFXSeed
GaingelsSeed
Peregrine VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 4, 2024

    Raised capital from NFX, Gaingels, and Peregrine Ventures.

  • Oct 19, 2021

    $315K round led by Peregrine Ventures.

Book a demo to see all signals

For institutional investors. Book with your work email.

Trojan Bio Filings

Explore SEC and related filing metadata, where available.

Trojan Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Trojan Bio's valuation, stock price, and market status.

Is Trojan Bio a public or private company?

Trojan Bio is a private company.

What is the current stock price of Trojan Bio?

Trojan Bio is a private company, so its shares have no public market price. Caplight tracks Trojan Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Trojan Bio worth (valuation)?

Trojan Bio's valuation is estimated at $3.0M based on funding round data.

Can I buy Trojan Bio stock?

Trojan Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Trojan Bio's last funding round?

Trojan Bio's most recent funding round was Seed on January 4, 2024.

Who are the main investors in Trojan Bio?

Key investors in Trojan Bio include NFX, Gaingels, Peregrine Ventures.

Will Trojan Bio IPO soon?

No public IPO plans have been announced for Trojan Bio.

How can I track Trojan Bio secondary market activity?

Caplight tracks bids, offers, and trades in Trojan Bio's shares on secondary markets.

Firmographic Details

HeadquartersNess Ziona
Employee Range4
Year Founded2021
Last FundingJan 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?